LAB
Standard BioTools Inc.
LAB offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO
Novo Nordisk A/S
NVO has the edge over LAB overall, supported by stronger fundamentals and lower modeled downside.
LAB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Unavailable |
LAB's profitability is currently stable, but its revenue and cash flow are under pressure. There isn't enough data to rate its balance sheet.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
LAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.65 | — |
| Cheap | 2.9x | $0.98 | +51% |
| Fair | 3.6x | $1.21 | +86% |
| Expensive | 4.7x | $1.61 | +147% |
Historical ranges are pointers, not guarantees.
LAB has the edge over NVO in the historical PE scenario, which offers more potential upside but is not a forecast.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
LAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect LAB's losses to grow, with revenue growing.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
NVO has the edge over LAB on the outlook, with more favorable earnings expectations.
LAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.34 | +$0.65 |
| Q2 2026 | $0.22 | +$0.51 |
| Q1 2026 | $0.20 | +$0.52 |
| Q4 2025 | -$0.20 | +$0.32 |
| Q3 2025 | -$0.31 | +$0.39 |
| Q2 2025 | -$0.29 | +$0.61 |
| Q1 2025 | -$0.32 | +$0.68 |
| Q4 2024 | -$0.52 | +$0.42 |
LAB has returned to profit: it earned $0.34 per share over the past year, after losing money the year before.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO's earnings per share have climbed steadily: $3.89 over the past year, up 4.9% from the year before, and higher year over year every quarter since late 2020.
LAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.4M | -0.9% |
| Q2 2026 | $20.1M | -7.6% |
| Q1 2026 | $21.1M | -48% |
| Q4 2025 | $23.8M | -49% |
| Q3 2025 | $19.6M | -57% |
| Q2 2025 | $21.8M | -42% |
| Q1 2025 | $40.8M | -10% |
| Q4 2024 | $46.7M | +66% |
LAB's revenue has slid since its 2024 peak: $19M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -102% | +67 points |
| Q2 2026 | -126% | -8.2 points |
| Q1 2026 | -59% | +22 points |
| Q4 2025 | -104% | -33 points |
| Q3 2025 | -168% | -98 points |
| Q2 2025 | -118% | +18 points |
| Q1 2025 | -81% | +51 points |
| Q4 2024 | -70% | +5.6 points |
LAB's operating margin was −102% last quarter, up 66 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over LAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over LAB on profitability, with a higher operating margin.
LAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.2M | +$16.9M |
| Q2 2026 | -$10.7M | +$11.9M |
| Q1 2026 | -$47.2M | -$11.8M |
| Q4 2025 | -$1.7M | +$15.8M |
| Q3 2025 | -$23.1M | +$7M |
| Q2 2025 | -$22.6M | +$18.4M |
| Q1 2025 | -$35.3M | +$27.9M |
| Q4 2024 | -$17.4M | -$3.3M |
LAB has burned cash in almost every quarter: −$66M over the past year, against −$98M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over LAB on cash generation, producing positive trailing cash flow while its opponent burns cash.
LAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.7M shares |
| 1 year | +2.9% | +10.9M shares |
| 3 years | +397% | +314M shares |
| 5 years | +416% | +317M shares |
| Available history | +489% | +327M shares |
LAB has 394M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $29.4M |
| Q1 2024 | $11.1M |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over LAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
LAB Net Leverage
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
LAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 16.7 | Oversold |
LAB's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
LAB PE vs Healthcare Sector
| Metric | LAB | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 4 | 29 | 25 pts below |
LAB has the edge over NVO on valuation relative to its sector.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
LAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 1.5% below |
| 20 week MA | $0.74 | 12% below |
| 50 week MA | $0.97 | 33% below |
| 100 week MA | $1.14 | 43% below |
| 200 week MA | $1.66 | 61% below |
LAB is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over LAB on trend strength, trading above more of its moving averages.
LAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.36 | $6.48 | +93% |
| 2021 | $6.48 | $3.80 | -41% |
| 2022 | $3.80 | $1.35 | -64% |
| 2023 | $1.35 | $2.21 | +64% |
| 2024 | $2.21 | $1.82 | -18% |
| 2025 | $1.82 | $1.38 | -24% |
| 2026 YTD | $1.38 | $0.65 | -53% |
LAB has finished lower in four of the last six years. It's down 53% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over LAB on returns for 2026, with the stronger performance.